DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic LeukemiaElaine Willmore, Barbara W. Durkacz|Clinical Cancer Research|2008Cited by 91
PARP1 expression, activity and<i>ex vivo</i>sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaAshleigh Herriott, Elaine Willmore|Oncotarget|2015Cited by 30
Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical SignallingEvan A. Mulligan, Elaine Willmore|Cancers|2023Cited by 4